DOPF
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
DOPF, also known as 2,5-dimethoxy-4-(3-fluoropropyl)amphetamine, is a designer drug from the amphetamine and DOx families. It was first synthesised by Alexander Shulgin and David Nichols in 1989 but was never published at the time, and was finally disclosed in Daniel Trachsel's review of the field in 20131. It has a binding affinity (K i ) of 9 nM at the serotonin receptor 5-HT 2A but is not known to have been tested in humans. DOPF is a controlled substance in Canada under phenethylamine blanket-ban language.
DOPF, also known as 2,5-dimethoxy-4-(3-fluoropropyl)amphetamine, is a designer drug from the amphetamine and DOx families. It was first synthesised by Alexander Shulgin and David Nichols in 1989 but was never published at the time, and was finally disclosed in Daniel Trachsel's review of the field in 2013. It has a binding affinity (K i ) of 9 nM at the serotonin receptor 5-HT 2A but is not known to have been tested in humans. DOPF is a controlled substance in Canada under phenethylamine blanket-ban language. ==External links== DOPF - Isomer Design
Text derived from https://en.wikipedia.org/w/index.php?oldid=1377228809 under CC BY-SA 4.0; modifications have been made.